A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

Authors:
  • NDNaval Daver
    Naval Daver
  • RARita Assi
    Rita Assi
  • FRFarhad Ravandi
    Farhad Ravandi
  • GGGuillermo Garcia-Manero
    Guillermo Garcia-Manero
  • EJElias Jabbour
    Elias Jabbour
  • CDCourtney D. DiNardo
    Courtney D. DiNardo
  • TKTapan M. Kadia
    Tapan M. Kadia
  • JNJing Ning
    Jing Ning
  • GNGraciela Nogueras-Gonzalez
    Graciela Nogueras-Gonzalez
  • SPSherry Pierce
    Sherry Pierce
  • DGDan Gombos
    Dan Gombos
  • SKSteven Kornblau
    Steven Kornblau

Abstract
No abstract available